Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (9264)	6/5/2002 9:31:26 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9719

>> Margin Call, Sold 14000 BTRN shares at closing price of $3.05. << This is a great example of "perspective" in biotech investing. BTRN has performed like crap, correct? I recommended BTRN as a VDXX component on 03.12.98, after biotech had been beaten to near death, summer '98. Low priced biotechs, lacking sponsorship, had been left to a new breed of funds, hedge funds that were willing to attack/short in the sector. The closing price that day was $1.75. It was "purchased" at $2.25 on 15.01.99 (there were subsequent purchases for the portfolio, but, hey, we're talking "perspective" here)....... Message 7311182 The perspective? Since then, BTRN has done almost everything wrong at each and any elective turn. Nonetheless, a well-timed purchase has done better than a bank account. Biotech has, after a string of bad performances and a monstrous bear, again been set upon by hedge funds. Many quality companies are selling at a modest multiple to cash, if not below it.